Opioid Crisis: USP’s Comments to the FDA

As government agencies consider solutions to the growing opioid crisis, the Food and Drug Administration (FDA) recently sought public comment about ways to best address this national emergency. USP was pleased to provide our perspective about how public standards might help support the agency’s efforts, and to report on our recent discussions with stakeholders and the standards being considered by USP’s Healthcare Quality Expert Committee.  


Compendium, compendia, compendial: Clearing up the mystery of these terms

In conversations about the role of quality standards in public health, you might come across the words “compendia” and “compendial.” At USP, terms like “compendial approaches,” “compendial standards,” and “compendial tools” are part of our everyday vocabulary. But their meaning can be a bit of a mystery to people who work outside of the pharmaceutical industry and regulatory bodies.


Can changes to prescription labels and other public standards help tame the opioid crisis?

The opioid crisis in the U.S. seems to be part of nearly every news broadcast and news site today. And based on the number of people affected by this crisis, serious conversations about how to help are more important than ever. The CDC estimates that more than 100 Americans die every day from an opioid overdose. And nearly 12 million people – close to 4% of the U.S.